Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 15/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 14/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.74 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.67 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.66 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2503389 | 0.99 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL14303749 | 0.99 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| Hydrochloric Acid SCHEMBL6581830 | 0.99 | CHRNA3 (0.98) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL13322058 | 0.91 | CHRNB2 (0.94) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL6584306 | 0.90 | CHRNB2 (0.92) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL6584638 | 0.90 | CHRNB2 (0.92) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL12122171 | 0.90 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL14311700 | 0.90 | CHRNA3 (0.81) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL7672186 | 0.90 | CHRNB2 (0.92) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 | |
| SCHEMBL12190831 | 0.90 | CHRNA3 (0.81) | CHRNA3CHRNB2CHRNB4CHRNA2CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | claimed |
| US-8729103-B2 | Silent desensitizers of neuronal nAChR and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110281836-A1 | Silent desensitizers of neuronal NACHR and methods of use thereof | PSYCHOGENICS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110269733-A1 | Silent Desensitizers of Neuronal nAChR and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNA3 20/4885CHRNB2 36/4885CHRNB4 26/4885 |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNA3 10/4885CHRNB2 7/4885CHRNB4 11/4885 |
| US-20110281836-A1 | Silent desensitizers of neuronal NACHR and methods of use thereof | CHRNA2, CHRNA5, CHRNB2 | CHRNA3 9/4885CHRNB2 3/4885CHRNB4 5/4885 |
| US-20110269733-A1 | Silent Desensitizers of Neuronal nAChR and Methods of Use Thereof | CHRNA2, CHRNA5, CHRNB2 | CHRNA3 9/4885CHRNB2 3/4885CHRNB4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.